PXD015957 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma |
Description | Predicting the outcome of immunotherapy treatment in melanoma patients is challenging. Alterations in genes involved in antigen presentation and the interferon gamma (IFN) pathway play an important role in the immune response to tumors. We describe here that the overexpression of PSMB8 and PSMB9, two components of the immunoproteasome, is predictive of better survival and improved response to immune-checkpoint inhibitors of melanoma patients. We study the mechanism that underlies this connection by analyzing the antigenic peptide repertoire of cells that overexpress these subunits using HLA peptidomics. We find a higher response of patient-matched tumor infiltrating lymphocytes against antigens deferentially presented after immunoproteasome overexpression. which may explain the higher immune infiltration observed in patients with high immunoproteasome expression levels. Importantly, we find that PSMB8 and PSMB9 expression levels are much stronger predictors of melanoma patients immune response to checkpoint inhibitors than the tumors mutational burden. Taken together, these results suggest that their expression levels can serve as important biomarkers for stratifying melanoma patients for immune-checkpoint treatment. |
HostingRepository | PRIDE |
AnnounceDate | 2024-10-22 |
AnnouncementXML | Submission_2024-10-22_03:59:02.256.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Shelly Kalaora |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | No PTMs are included in the dataset |
Instrument | Q Exactive |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2019-10-22 03:04:33 | ID requested | |
1 | 2020-02-21 01:15:10 | announced | |
⏵ 2 | 2024-10-22 03:59:10 | announced | 2024-10-22: Updated project metadata. |
Publication List
10.1038/s41467-020-14639-9; |
Kalaora S, Lee JS, Barnea E, Levy R, Greenberg P, Alon M, Yagel G, Bar Eli G, Oren R, Peri A, Patkar S, Bitton L, Rosenberg SA, Lotem M, Levin Y, Admon A, Ruppin E, Samuels Y, Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. Nat Commun, 11(1):896(2020) [pubmed] |
Keyword List
submitter keyword: immunoproteasome, neoantigens, melanoma, tumor associated antigens,HLA peptidomics |
Contact List
Yardena Samuels |
contact affiliation | Molecular cell biology department Weizmann Institute of Science |
contact email | yardena.samuels@weizmann.ac.il |
lab head | |
Shelly Kalaora |
contact affiliation | Weizmann institute of science |
contact email | shelly.kalaora@weizmann.ac.il |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015957 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD015957
- Label: PRIDE project
- Name: Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma